BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-1873. [PMID: 16055434 DOI: 10.1373/clinchem.2005.048389] [Cited by in Crossref: 362] [Cited by in F6Publishing: 330] [Article Influence: 21.3] [Reference Citation Analysis]
Number Citing Articles
1 Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C: Combination algorithms for liver fibrosis in HCV. Alimentary Pharmacology & Therapeutics 2012;35:92-104. [DOI: 10.1111/j.1365-2036.2011.04897.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
2 Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Biomarkers of liver fibrosis. Adv Clin Chem. 2008;46:131-160. [PMID: 19004189 DOI: 10.1016/s0065-2423(08)00404-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
3 Świderska M, Jaroszewicz J, Parfieniuk-Kowerda A, Rogalska-Płońska M, Stawicka A, Panasiuk A, Flisiak R. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators Inflamm 2017;2017:3480234. [PMID: 28827897 DOI: 10.1155/2017/3480234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
4 Karagoz E, Ulcay A, Tanoglu A, Kara M, Turhan V, Erdem H, Oncul O, Gorenek L. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26:1320-1324. [PMID: 25210777 DOI: 10.1097/meg.0000000000000203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
5 Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T. FibroMAX: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 2007;7:481-90. [PMID: 17892356 DOI: 10.1586/14737159.7.5.481] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
6 Chrostek L, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20(25): 8018-8023 [PMID: 25009372 DOI: 10.3748/wjg.v20.i25.8018] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
7 Dufour DR. Assessment of liver fibrosis: Can serum become the sample of choice. Clin Chem. 2005;51:1763-1764. [PMID: 16189374 DOI: 10.1373/clinchem.2005.056929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, Bosson JL, Guyader D, Renversez JC, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Ledinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fouchard Hubert I, Bailly F, Vaubourdolle M;  ANRS HCEP 23 Fibrostar Group. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56:55-62. [PMID: 21781944 DOI: 10.1016/j.jhep.2011.05.024] [Cited by in Crossref: 142] [Cited by in F6Publishing: 126] [Article Influence: 12.9] [Reference Citation Analysis]
9 Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Review of Gastroenterology & Hepatology 2019;13:361-74. [DOI: 10.1080/17474124.2019.1579641] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
10 Vergniol J, Foucher J, Castéra L, Bernard PH, Tournan R, Terrebonne E, Chanteloup E, Merrouche W, Couzigou P, de Lédinghen V. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat. 2009;16:132-140. [PMID: 19175875 DOI: 10.1111/j.1365-2893.2008.01055.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 5.6] [Reference Citation Analysis]
11 Fragkos KC, Picasso Bouroncle MC, Kumar S, Caselton L, Menys A, Bainbridge A, Taylor SA, Torrealdea F, Kumagai T, Di Caro S, Rahman F, Macnaughtan J, Chouhan MD, Mehta S. Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study. Nutrients 2020;12:E2151. [PMID: 32707726 DOI: 10.3390/nu12072151] [Reference Citation Analysis]
12 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
13 Strasser SI. Managing hepatitis C in general practice. Aust Prescr 2017;40:64-9. [PMID: 28507399 DOI: 10.18773/austprescr.2017.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Geramizadeh B, Janfeshan K, Saberfiroozi M. Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol. 2008;14:174-177. [PMID: 19568533 DOI: 10.4103/1319-3767.43274] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
15 Massart C, Bendavid C, Gibassier J, Perrin M, Deugnier Y, Lainé F. Importance of the functional sensitivity determination of a serum hyaluronic acid assay for the prediction of liver fibrosis in patients with features of the metabolic syndrome. Clinical Chemistry and Laboratory Medicine (CCLM) 2006;44. [DOI: 10.1515/cclm.2006.076] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Halfon P. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02. Journal of Hepatology 2008;48:765-73. [DOI: 10.1016/j.jhep.2008.01.025] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
17 Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:666-75. [PMID: 24061203 DOI: 10.1038/nrgastro.2013.175] [Cited by in Crossref: 168] [Cited by in F6Publishing: 146] [Article Influence: 18.7] [Reference Citation Analysis]
18 Zarski JP, Sturm N, Guechot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One. 2013;8:e59088. [PMID: 23555619 DOI: 10.1371/journal.pone.0059088.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Forns X. Diagnosis of liver fibrosis in 2008. Gastroentérologie Clinique et Biologique 2008;32:1-3. [DOI: 10.1016/s0399-8320(08)73988-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Kim SG, Kim YS, Jung SW, Kim HK, Jang JY, Moon JH, Kim HS, Lee JS, Lee MS, Shim CS, Kim BS. The usefulness of transient elastography to diagnose cirrhosis in patients with alcoholic liver disease. Korean J Hepatol 2009;15:42. [DOI: 10.3350/kjhep.2009.15.1.42] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
21 Parsian H, Alizadeh M, Negahdar H. Would the physicians eventually obsolete the liver biopsy for the assessment of liver fibrosis? Hepat Mon 2012;12:353-4. [PMID: 22783349 DOI: 10.5812/hepatmon.6227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Wu S, Ni Y, Liu L, Li H, Lu L, Wang J. Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2012;6:360-8. [DOI: 10.1007/s12072-011-9328-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
23 Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, Heller T, Koh C. Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2017;45:127-138. [PMID: 27813124 DOI: 10.1111/apt.13834] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
24 Guéchot J, Lasnier E, Sturm N, Paris A, Zarski JP. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta. 2010;411:86-91. [PMID: 19850017 DOI: 10.1016/j.cca.2009.10.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
25 Duarte-rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Annals of Hepatology 2012;11:426-39. [DOI: 10.1016/s1665-2681(19)31456-5] [Cited by in Crossref: 31] [Article Influence: 3.1] [Reference Citation Analysis]
26 Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75. [PMID: 22720279 DOI: 10.1155/2012/947676] [Cited by in Crossref: 40] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
27 Moqueet N, Kanagaratham C, Gill MJ, Hull M, Walmsley S, Radzioch D, Saeed S, Platt RW, Klein MB; Canadian Co-infection Cohort Study (CTN 222). A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. PLoS One 2017;12:e0176282. [PMID: 28467457 DOI: 10.1371/journal.pone.0176282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zarski JP, Sturm N, Guechot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One 2013;8:e59088. [PMID: 23555619 DOI: 10.1371/journal.pone.0059088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
29 Fernandes FF, Ferraz ML, Andrade LE, Dellavance A, Terra C, Pereira G, Pereira JL, Campos F, Figueiredo F, Perez RM. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients. J Clin Gastroenterol. 2015;49:235-241. [PMID: 24714186 DOI: 10.1097/mcg.0000000000000128] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
30 Lubner MG, Pickhardt PJ. Multidetector Computed Tomography for Retrospective, Noninvasive Staging of Liver Fibrosis. Gastroenterol Clin North Am 2018;47:569-84. [PMID: 30115438 DOI: 10.1016/j.gtc.2018.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
31 Mendes LC, Ferreira PA, Miotto N, Zanaga L, Gonçales E, Lazarini MS, Gonçales FL Júnior, Stucchi RS, Vigani AG. Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. Braz J Med Biol Res 2016;49:e5432. [PMID: 27533769 DOI: 10.1590/1414-431X20165432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008;38:762-9. [PMID: 18462378 DOI: 10.1111/j.1872-034X.2008.00364.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
33 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
34 Fitzpatrick E, Quaglia A, Vimalesvaran S, Basso MS, Dhawan A. Transient elastography is a useful noninvasive tool for the evaluation of fibrosis in paediatric chronic liver disease. J Pediatr Gastroenterol Nutr. 2013;56:72-76. [PMID: 22922372 DOI: 10.1097/mpg.0b013e31826f2760] [Cited by in Crossref: 83] [Cited by in F6Publishing: 30] [Article Influence: 9.2] [Reference Citation Analysis]
35 Bertrais S, Boursier J, Ducancelle A, Oberti F, Fouchard-Hubert I, Moal V, Calès P. Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests. J Gastroenterol Hepatol 2017;32:1240-9. [PMID: 27897323 DOI: 10.1111/jgh.13668] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. Best Pract Res Clin Gastroenterol. 2013;27:577-596. [PMID: 24090944 DOI: 10.1016/j.bpg.2013.08.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
37 Arienti V, Aluigi L, Pretolani S, Accogli E, Polimeni L, Domanico A, Violi F. Ultrasonography (US) and non-invasive diagnostic methods for non-alcoholic fatty liver disease (NAFLD) and early vascular damage. Possible application in a population study on the metabolic syndrome (MS). Intern Emerg Med. 2012;7 Suppl 3:S283-S290. [PMID: 23073869 DOI: 10.1007/s11739-012-0824-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
38 Ebrahimi H, Naderian M, Sohrabpour AA. New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis. 2016;8:166-178. [PMID: 27698966 DOI: 10.15171/mejdd.2016.29] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
39 Huang Y, Joseph J, de Boer WB, Cheng W, Adams LA, MacQuillan G, Garas G, Raftopoulos S, Jeffrey GP. Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia. Clin Gastroenterol Hepatol 2020;18:496-504.e3. [PMID: 31319186 DOI: 10.1016/j.cgh.2019.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
40 Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A, Botta D, Renou C, Bréchot MC. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:395-402. [PMID: 17156890 DOI: 10.1016/j.jhep.2006.09.020] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
41 Hernández-Bartolomé A, López-Rodríguez R, Rodríguez-Muñoz Y, Martín-Vílchez S, Borque MJ, García-Buey L, González-Moreno L, Real Y, Moreno-Otero R, Sanz-Cameno P. Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. PLoS One 2013;8:e66143. [PMID: 23823085 DOI: 10.1371/journal.pone.0066143] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
42 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Vallet-pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-venier V, Fontaine H, Pol S. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6. [DOI: 10.1002/hep.21669] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 981] [Article Influence: 68.4] [Reference Citation Analysis]
44 Jarcuska P, Janicko M, Veselíny E, Jarcuska P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010;411:1009-1017. [PMID: 20399764 DOI: 10.1016/j.cca.2010.04.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
45 Nguyen-khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly J, Brevet M, Grignon P, Lion S, Le Page L, Dupas J. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Alimentary Pharmacology & Therapeutics 2008;28:1188-98. [DOI: 10.1111/j.1365-2036.2008.03831.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 120] [Article Influence: 10.4] [Reference Citation Analysis]
46 Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, Huang Y, Adams LA. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int. 2018;38:1793-1802. [PMID: 29575516 DOI: 10.1111/liv.13739] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
47 Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozguneş N, Colak O, Gunduz A, Senates E, Ozaras R. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. Wien Klin Wochenschr. 2013;125:453-460. [PMID: 23860694 DOI: 10.1007/s00508-013-0394-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
48 Adams LA, Angulo P. Role of Liver Biopsy and Serum Markers of Liver Fibrosis in Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease 2007;11:25-35. [DOI: 10.1016/j.cld.2007.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
49 Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology. 2009;49:97-105. [PMID: 19053048 DOI: 10.1002/hep.22576] [Cited by in Crossref: 183] [Cited by in F6Publishing: 159] [Article Influence: 14.1] [Reference Citation Analysis]
50 Zarski J, Bedossa P, Bronowicki J, Doffoel M, Poynard T. Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l’hépatite C. Gastroentérologie Clinique et Biologique 2007;31:34-9. [DOI: 10.1016/s0399-8320(07)92561-0] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
51 Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134:1670-1681. [PMID: 18471546 DOI: 10.1053/j.gastro.2008.03.001] [Cited by in Crossref: 289] [Cited by in F6Publishing: 271] [Article Influence: 20.6] [Reference Citation Analysis]
52 Park SH, Kim CH, Kim DJ, Suk KT, Park JH, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Park HY, Kim YB. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C. Clinical Biochemistry 2011;44:1396-9. [DOI: 10.1016/j.clinbiochem.2011.08.1151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
53 Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2013;7:356-68. [PMID: 26201770 DOI: 10.1007/s12072-013-9439-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
54 Cervoni JP, Alby-Lepresle B, Weil D, Zhong P, Aubin F, Wendling D, Toussirot E, Vuitton L, Carbonnel F, Blondet R, Thévenot T, Calès P, Monnet E, Di Martino V. A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy. Clin Res Hepatol Gastroenterol 2020;44S:100003. [PMID: 33602481 DOI: 10.1016/j.clirex.2020.100003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, Lin YH. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 2012; 18(8): 746-753 [PMID: 22371634 DOI: 10.3748/wjg.v18.i8.746] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
56 Lo Re V 3rd, Lynn K, Stumm ER, Long J, Nezamzadeh MS, Baker JF, Hoofnagle AN, Kapalko AJ, Mounzer K, Zemel BS, Tebas P, Kostman JR, Leonard MB. Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women. J Infect Dis 2015;212:924-33. [PMID: 25754980 DOI: 10.1093/infdis/jiv147] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
57 Crockett SD, Kaltenbach T, Keeffe EB. Do We Still Need a Liver Biopsy? Are the Serum Fibrosis Tests Ready for Prime Time? Clinics in Liver Disease 2006;10:513-34. [DOI: 10.1016/j.cld.2006.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
58 Ydreborg M, Lisovskaja V, Lagging M, Brehm Christensen P, Langeland N, Buhl MR, Pedersen C, Mørch K, Wejstål R, Norkrans G, Lindh M, Färkkilä M, Westin J. A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. PLoS One 2014;9:e93601. [PMID: 24699777 DOI: 10.1371/journal.pone.0093601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
59 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007;381:107-113. [PMID: 17399697 DOI: 10.1016/j.cca.2007.02.038] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 8.8] [Reference Citation Analysis]
60 Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical Features of Hepatitis C Virus Carriers With Persistently normal Alanine Aminotransferase Levels. Hepat Mon 2012;12:77-84. [DOI: 10.5812/hepatmon.4851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
61 Huang Y, Adams LA, Joseph J, Bulsara MK, Jeffrey GP. The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis. Liver Int 2017;37:121-31. [DOI: 10.1111/liv.13116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
62 Veillon P, Gallois Y, Moal V, Fouchard-Hubert I, Charles I, Larcher F, Dib N, Boursier J, Oberti F, Laafi J, Guéchot J, Balan V, Calès P, Lunel-Fabiani F. Assessment of new hyaluronic acid assays and their impact on FibroMeter scores. Clin Chim Acta 2011;412:347-52. [PMID: 21075099 DOI: 10.1016/j.cca.2010.11.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
63 Kaur N, Goyal G, Garg R, Tapasvi C, Chawla S, Kaur R. Potential role of noninvasive biomarkers during liver fibrosis. World J Hepatol 2021; 13(12): 1919-1935 [DOI: 10.4254/wjh.v13.i12.1919] [Reference Citation Analysis]
64 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
65 Adhoute X, Foucher J, Laharie D, Terrebonne E, Vergniol J, Castéra L, Lovato B, Chanteloup E, Merrouche W, Couzigou P. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol. 2008;32:180-187. [PMID: 18496894 DOI: 10.1016/j.gcb.2007.12.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
66 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
67 Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009;7:397-414; quiz 366. [PMID: 19114127 DOI: 10.1016/j.cgh.2008.11.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
68 Dhyani M, Anvari A, Samir AE. Ultrasound elastography: liver. Abdom Imaging 2015;40:698-708. [PMID: 25690689 DOI: 10.1007/s00261-015-0373-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
69 Afdhal NH, Curry M. Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol. 2007;46:543-545. [PMID: 17316879 DOI: 10.1016/j.jhep.2007.01.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
70 Galal GM, Amin NF, Abdel Hafeez HA, El-Baz MA. Can serum fibrosis markers predict medium/large oesophageal varices in patients with liver cirrhosis? Arab J Gastroenterol 2011;12:62-7. [PMID: 21684475 DOI: 10.1016/j.ajg.2011.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
71 Soresi M, Giannitrapani L, Cervello M, Licata A, Montalto G. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol 2014; 20(48): 18131-18150 [PMID: 25561782 DOI: 10.3748/wjg.v20.i48.18131] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
72 Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009;16:300-314. [PMID: 19254351 DOI: 10.1111/j.1365-2893.2009.01087.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
73 Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014; 20(45): 16820-16830 [PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 67] [Article Influence: 11.6] [Reference Citation Analysis]
74 Tural C, Tor J, Sanvisens A, Pérez-Alvarez N, Martínez E, Ojanguren I, García-Samaniego J, Rockstroh J, Barluenga E, Muga R, Planas R, Sirera G, Rey-Joly C, Clotet B. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009;7:339-45. [PMID: 19171202 DOI: 10.1016/j.cgh.2008.11.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
75 Chávez-tapia NC, Ridruejo E, de Mattos AA, Bessone F, Daruich J, Sánchez-ávila JF, Cheinquer H, Zapata R, Uribe M, Bosques-padilla F, Gadano A, Soza A, Dávalos-moscol M, Marroni C, Muñoz-espinoza L, Castro-narro G, Paraná R, Méndez-sánchez N. An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology 2013;12:S3-S35. [DOI: 10.1016/s1665-2681(19)31404-8] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
76 Nana J, Skaare K, Bosson JL, Leroy V, Asselah T, Adler M, Sturm N, Zarski JP. EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with hepatitis B: An independent validation. J Viral Hepat 2021;28:1169-76. [PMID: 34002927 DOI: 10.1111/jvh.13548] [Reference Citation Analysis]
77 Chrostek L, Przekop D, Gruszewska E, Gudowska-Sawczuk M, Cylwik B. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics. Biomed Res Int 2019;2019:3646975. [PMID: 31192254 DOI: 10.1155/2019/3646975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. Journal of Digestive Diseases 2009;10:7-14. [DOI: 10.1111/j.1751-2980.2008.00356.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
79 Sethi S, Simonetto DA, Abdelmoneim SS, Campion MB, Kaloiani I, Clayton AC, Kremers WK, Halling KC, Kamath PS, Talwalkar J, Shah VH. Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. J Clin Exp Hepatol 2012;2:19-26. [PMID: 25755402 DOI: 10.1016/S0973-6883(12)60078-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
80 Forbes TP, Lawrence J, Verkouteren JR, Verkouteren RM. Discriminative potential of ion mobility spectrometry for the detection of fentanyl and fentanyl analogues relative to confounding environmental interferents. Analyst 2019;144:6391-403. [PMID: 31579898 DOI: 10.1039/c9an01771b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
81 Croagh C, Lubel J. Advances in the management of hepatitis C: Advances in hepatitis C. Intern Med J 2013;43:1265-71. [DOI: 10.1111/imj.12304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
82 Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Rev Gastroenterol Hepatol 2008;5:95-106. [DOI: 10.1038/ncpgasthep1025] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 8.8] [Reference Citation Analysis]
83 Day J, Patel P, Parkes J, Rosenberg W. Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. J Appl Lab Med. 2019;3:815-826. [PMID: 31639756 DOI: 10.1373/jalm.2018.027359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
84 Scott R, Guha IN. Non-invasive monitoring of liver fibrosis. British Medical Bulletin 2014;112:97-106. [DOI: 10.1093/bmb/ldu031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
85 Boursier J, Rousselet M, Aubé C, Calès P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics 2012;6:381-94. [DOI: 10.1517/17530059.2012.691878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
86 Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism 2021;123:154868. [PMID: 34400217 DOI: 10.1016/j.metabol.2021.154868] [Reference Citation Analysis]
87 Kalantari H, Hoseini H, Babak A, Yaran M. Validation of hepascore as a predictor of liver fibrosis in patients with chronic hepatitis C infection. Hepat Res Treat. 2011;2011:972759. [PMID: 22254137 DOI: 10.1155/2011/972759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
88 Sagir A, Glaubach B, Sahin K, Graf D, Erhardt A, Oette M, Häussinger D. Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infect Dis Ther 2015;4:355-64. [PMID: 26143457 DOI: 10.1007/s40121-015-0073-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
89 Boursier J, Vergniol J, Guillet A, Hiriart J, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-hubert I, Rousselet M, Calès P, de Lédinghen V. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Journal of Hepatology 2016;65:570-8. [DOI: 10.1016/j.jhep.2016.04.023] [Cited by in Crossref: 183] [Cited by in F6Publishing: 156] [Article Influence: 30.5] [Reference Citation Analysis]
90 Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94:515-534. [PMID: 23623211 DOI: 10.1016/j.diii.2013.02.005] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 12.2] [Reference Citation Analysis]
91 Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18(39): 5514-5520 [PMID: 23112543 DOI: 10.3748/wjg.v18.i39.5514] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
92 Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, Leung N, Tozun N, Hamid S, Jafri W, Maruyama H, Bedossa P, Pinzani M, Chawla Y, Esmat G, Doss W, Elzanaty T, Sakhuja P, Nasr AM, Omar A, Wai CT, Abdallah A, Salama M, Hamed A, Yousry A, Waked I, Elsahar M, Fateen A, Mogawer S, Hamdy H, Elwakil R, Jury of the APASL Consensus Development Meeting 29 January 2008 on Liver Fibrosis With Without Hepatitis B or C. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 2009;3:323-333. [PMID: 19669358 DOI: 10.1007/s12072-008-9114-x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
93 Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C. Discordance between biochemical markers of liver activity and fibrosis (Actitest®–Fibrotest®) and liver biopsy in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 2008;32:858-65. [DOI: 10.1016/j.gcb.2008.05.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
94 De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int. 2010;4:375-385. [PMID: 20305757 DOI: 10.1007/s12072-009-9160-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
95 Vergniol J, de Ledinghen V. Diagnostic non invasif de la fibrose hépatique : modalités pratiques d’utilisation des marqueurs sanguins et du FibroScan. Gastroentérologie Clinique et Biologique 2009;33:334-44. [DOI: 10.1016/j.gcb.2009.02.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
96 Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011;5:625-634. [PMID: 21484142 DOI: 10.1007/s12072-010-9240-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
97 Mccaughan G. Advances in viral hepatitis: 50 years of Australian gastroenterology. Journal of Gastroenterology and Hepatology 2009;24:S132-5. [DOI: 10.1111/j.1440-1746.2009.06082.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Chen Y, Wang Y, Chen Y, Yu Z, Chi X, Hu KQ, Li Q, Tan L, Xiang D, Shang Q, Lei C, Chen L, Hu X, Wang J, Liu H, Lu W, Chi W, Dong Z, Wang X, Li Z, Xiao H, Chen D, Bai W, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Sun H, Deng M, Qi X, Zhang Z, Qi X, Yang Y. A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. Clin Transl Gastroenterol 2019;10:1-12. [PMID: 31033506 DOI: 10.14309/ctg.0000000000000033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Costelloe SJ, Theocharidou E, Tsochatzis E, Thalassinos E, Martin N, Fede G, Thomas M, Burroughs AK. Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology. European Journal of Gastroenterology & Hepatology 2015;27:313-20. [DOI: 10.1097/meg.0000000000000267] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Deng H, Qi X, Peng Y, Li J, Li H, Zhang Y, Liu X, Sun X, Guo X. Diagnostic Accuracy of APRI, AAR, FIB-4, FI, and King Scores for Diagnosis of Esophageal Varices in Liver Cirrhosis: A Retrospective Study. Med Sci Monit 2015;21:3961-77. [PMID: 26687574 DOI: 10.12659/msm.895005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
101 Lubner MG, Jones D, Kloke J, Said A, Pickhardt PJ. CT texture analysis of the liver for assessing hepatic fibrosis in patients with hepatitis C virus. Br J Radiol 2019;92:20180153. [PMID: 30182750 DOI: 10.1259/bjr.20180153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
102 Wang Z, Huang Y, Nossent H, Chan JJ, Adams LA, Joseph J, Cheng W, Garas G, MacQuillan G, Jeffrey GP. Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users: A retrospective cohort study. JGH Open 2020;4:1211-6. [PMID: 33319058 DOI: 10.1002/jgh3.12430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J. 2008;411:1-18. [PMID: 18333835 DOI: 10.1042/bj20071570] [Cited by in Crossref: 217] [Cited by in F6Publishing: 110] [Article Influence: 15.5] [Reference Citation Analysis]
104 Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, Ching HLI, Bulsara M, Jeffrey GP. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease: Fibrosis models in NAFLD. Journal of Gastroenterology and Hepatology 2011;26:1536-43. [DOI: 10.1111/j.1440-1746.2011.06774.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 9.5] [Reference Citation Analysis]
105 Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 2012;12:177-184. [PMID: 22550525 DOI: 10.5812/hepatmon.853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
106 Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol 2016; 22(29): 6663-6672 [PMID: 27547009 DOI: 10.3748/wjg.v22.i29.6663] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
107 Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki EI, Shimomura S, Iijima H, Nakamura H, Nishiguchi S. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol 2012; 4(1): 11-17 [PMID: 22312451 DOI: 10.4254/wjh.v4.i1.11] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
108 Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325-335. [PMID: 21254180 DOI: 10.1002/hep.24013] [Cited by in Crossref: 272] [Cited by in F6Publishing: 248] [Article Influence: 22.7] [Reference Citation Analysis]
109 Sturm N, Marlu A, Arvers P, Zarski JP, Leroy V. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C. Liver Int 2013;33:428-38. [PMID: 23402612 DOI: 10.1111/liv.12092] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
110 Attallah AM, Omran MM, Farid K, El-Bendary M, Emran TM, Albannan MS, El-Dosoky I. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta. 2012;413:1725-1730. [PMID: 22759976 DOI: 10.1016/j.cca.2012.06.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
111 Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011;18:23-31. [PMID: 20196799 DOI: 10.1111/j.1365-2893.2009.01263.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 109] [Article Influence: 9.8] [Reference Citation Analysis]
112 Ong SY, Khoo T, Nicoll AJ, Gurrin L, Worland T, Pateria P, Ramm LE, Testro A, Anderson GJ, Skoien R, Powell LW, Ramm GA, Olynyk JK, Delatycki MB. Utility and limitations of Hepascore and transient elastography to detect advanced hepatic fibrosis in HFE hemochromatosis. Sci Rep 2021;11:14654. [PMID: 34282177 DOI: 10.1038/s41598-021-94083-x] [Reference Citation Analysis]
113 Cheung KJ, Tilleman K, Deforce D, Colle I, Moreno C, Gustot T, Van Vlierberghe H. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23:701-710. [PMID: 21623191 DOI: 10.1097/meg.0b013e3283471b74] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
114 Vergara M, Bejarano G, Dalmau B, Gil M, Miquel M, Sanchez-Delgado J, Casas M, Puig J, Martinez-Bauer E, Dosal A, Lopez M, Moreno L, Valero O, Bella MR, Calvet X. Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2015;27:826-33. [PMID: 26043289 DOI: 10.1097/MEG.0000000000000346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
115 Bracht T, Mölleken C, Ahrens M, Poschmann G, Schlosser A, Eisenacher M, Stühler K, Meyer HE, Schmiegel WH, Holmskov U, Sorensen GL, Sitek B. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. J Transl Med 2016;14:201. [PMID: 27378383 DOI: 10.1186/s12967-016-0952-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
116 Qu Y, Gao C, Zhou K, Zhao Y, Xu M, Lu L. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Annals of Hepatology 2012;11:202-12. [DOI: 10.1016/s1665-2681(19)31025-7] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
117 Muñoz-espinosa LE, Trujillo-trujillo ME, Martínez-macías RF, Panduro A, Rivas-estilla AM, Fierro NA, Silvera-linares AL, Torres-valadez R, Cordero-pérez P, González-aldaco K, Chen-lópez CY, José-abrego A, Zuñiga-noriega JR, Gutiérrez-ruiz MC, Roman S. Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals of Hepatology 2015;14:642-51. [DOI: 10.1016/s1665-2681(19)30758-6] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
118 Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. J Gastroenterol Hepatol 2018;33:291-7. [PMID: 28548299 DOI: 10.1111/jgh.13834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
119 Boursier J, Isselin G, Fouchard-Hubert I, Oberti F, Dib N, Lebigot J, Bertrais S, Gallois Y, Calès P, Aubé C. Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. Eur J Gastroenterol Hepatol. 2010;22:1074-1084. [PMID: 20440210 DOI: 10.1097/meg.0b013e328339e0a1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 37] [Article Influence: 8.1] [Reference Citation Analysis]
120 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 787] [Article Influence: 131.1] [Reference Citation Analysis]
121 Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-856 [PMID: 28740596 DOI: 10.4254/wjh.v9.i19.850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
122 Lambrecht J, Verhulst S, Mannaerts I, Reynaert H, van Grunsven LA. Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard? Biochim Biophys Acta Mol Basis Dis. 2018;1864:1024-1036. [PMID: 29329986 DOI: 10.1016/j.bbadis.2018.01.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
123 Pockros PJ. Noninvasive Markers of Fibrosis in Chronic Hepatitis Patients: . Journal of Clinical Gastroenterology 2006;40:461-3. [DOI: 10.1097/00004836-200607000-00001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
124 Nguyen-khac E. Résultats et place du Fibroscan® dans le diagnostic non invasif de la fibrose hépatique. La Revue de Médecine Interne 2007;28:94-102. [DOI: 10.1016/j.revmed.2006.10.329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
125 Taibi L, Boyd A, Bosselut N, Bottero J, Guéchot J, Lacombe K, Lasnier E, Baudin B, Vaubourdolle M. Diagnostic accuracy of the Coopscore© to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection. Ann Clin Biochem 2018;55:236-43. [PMID: 28661201 DOI: 10.1177/0004563217707979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Khalili H, Dayyeh BA, Friedman LS. Assessment of Liver Function in Clinical Practice. In: Ginès P, Kamath PS, Arroyo V, editors. Chronic Liver Failure. Totowa: Humana Press; 2011. pp. 47-76. [DOI: 10.1007/978-1-60761-866-9_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
127 Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes Metab J. 2019;43:31-45. [PMID: 30793550 DOI: 10.4093/dmj.2019.0011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 20.0] [Reference Citation Analysis]
128 Smirne C, Rigamonti C, De Benedittis C, Sainaghi PP, Bellan M, Burlone ME, Castello LM, Avanzi GC. Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis. Dis Markers 2019;2019:2304931. [PMID: 31583026 DOI: 10.1155/2019/2304931] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
129 Wang Z, Bertot LC, Jeffrey GP, Joseph J, Garas G, de Boer B, Huang Y, MacQuillan G, Wallace M, Smith B, Adams LA. Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01055-7. [PMID: 34624564 DOI: 10.1016/j.cgh.2021.09.040] [Reference Citation Analysis]
130 Huang H, Wu T, Mao J, Fang Y, Zhang J, Wu L, Zheng S, Lin B, Pan H. CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis. OMICS. 2015;19:339-345. [PMID: 26415140 DOI: 10.1089/omi.2015.0037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
131 Boursier J, Dib N, Oberti F, Calès P. Caractéristiques et interprétation des tests sanguins de fibrose hépatique. Gastroentérologie Clinique et Biologique 2007;31:511-23. [DOI: 10.1016/s0399-8320(07)89421-8] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
132 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
133 Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol. 2016;7:159. [PMID: 27378924 DOI: 10.3389/fphar.2016.00159] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
134 Papastamataki M, Delaporta P, Premetis E, Kattamis A, Ladis V, Papassotiriou I. Evaluation of liver fibrosis in patients with thalassemia: The important role of hyaluronic acid. Blood Cells, Molecules, and Diseases 2010;45:215-8. [DOI: 10.1016/j.bcmd.2010.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
135 Alboraie M, Khairy M, Elsharkawy A, Elsharkawy M, Asem N, Abo El-Seoud AR, Elghamry FG, Esmat G. Egy-score as a noninvasive score for the assessment of hepatic fibrosis in chronic hepatitis C: a preliminary approach. Saudi J Gastroenterol. 2014;20:170-174. [PMID: 24976280 DOI: 10.4103/1319-3767.133003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
136 Başar O, Yimaz B, Ekiz F, Giniş Z, Altinbaş A, Aktaş B, Tuna Y, Çoban S, Delibaş N, Yüksel O. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013;37:152-8. [PMID: 23391746 DOI: 10.1016/j.clinre.2012.07.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
137 Kitson MT, Kemp WW, Iser DM, Paul E, Wilson JW, Roberts SK. Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease. Liver Int 2013;33:698-705. [PMID: 23432782 DOI: 10.1111/liv.12113] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
138 Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J Hepatol. 2012;2012:231210. [PMID: 22530132 DOI: 10.1155/2012/231210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
139 Attallah AM, Toson EA, El-waseef AM, Abo-seif MA, Omran MM, Shiha GE. Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection. Clinica Chimica Acta 2006;369:66-72. [DOI: 10.1016/j.cca.2006.01.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
140 Tachi Y, Hirai T, Toyoda H, Tada T, Hayashi K, Honda T, Ishigami M, Goto H, Kumada T. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One 2015;10:e0133515. [PMID: 26214180 DOI: 10.1371/journal.pone.0133515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
141 Boursier J, Bacq Y, Halfon P, Leroy V, de Ledinghen V, de Muret A, Bourlière M, Sturm N, Foucher J, Oberti F, Rousselet MC, Calès P. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C: . European Journal of Gastroenterology & Hepatology 2009;21:28-38. [DOI: 10.1097/meg.0b013e32830cebd7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
142 Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol. 2008;32:52-57. [PMID: 18973846 DOI: 10.1016/s0399-8320(08)73993-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
143 El-mezayen HA, Toson el-SA, Shiha GE. Role of hyaluronic acid, its degrading enzymes, degradation products, and ferritin in the assessment of fibrosis stage in Egyptian patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2013;25:69-76. [PMID: 23011038 DOI: 10.1097/meg.0b013e3283594924] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
144 Calès P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N, Zarski JP, Rousselet MC. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem. 2010;43:1315-1322. [PMID: 20713037 DOI: 10.1016/j.clinbiochem.2010.08.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
145 Nielsen MJ, Kazankov K, Leeming DJ, Karsdal MA, Krag A, Barrera F, McLeod D, George J, Grønbæk H. Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. PLoS One 2015;10:e0137302. [PMID: 26406331 DOI: 10.1371/journal.pone.0137302] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
146 Lavaill L, Dussaucy A, Bardonnet K, Duraffourg N, Monnet E, Thévenot T, Davani S, Di Martino V; DEFI-HOSP Group. Automatic detection of cirrhosis in hospitalized patients: a pragmatic experience. Eur J Gastroenterol Hepatol 2016;28:74-81. [PMID: 26317562 DOI: 10.1097/MEG.0000000000000464] [Reference Citation Analysis]
147 Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 2012;12:177-184. [PMID: 22550525 DOI: 10.5812/hepatmon.5106] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
148 Alboraie MA, Afifi ME, Elghamry FG, Shalaby HA, Elshennawy GE, Abdelaziz AA, Shaheen MU, Abo El-Seoud AR. Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study. Hepat Mon 2013;13:e10810. [PMID: 24046790 DOI: 10.5812/hepatmon.10810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
149 Kim SU, Han KH, Ahn SH. Non-invasive assessment of liver fibrosis: the gap between ideal and real. J Gastroenterol Hepatol. 2011;26:937-939. [PMID: 21564284 DOI: 10.1111/j.1440-1746.2011.06741.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
150 Takaki S, Kawakami Y, Miyaki D, Nakahara T, Naeshiro N, Murakami E, Tanaka M, Honda Y, Yokoyama S, Nagaoki Y. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. Hepatol Res. 2014;44:280-287. [PMID: 23607728 DOI: 10.1111/hepr.12129] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
151 Miyata M, Kuroda M, Unakami M, Tasaki K, Migita K, Ohira H. Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. Modern Rheumatology 2019;29:936-42. [DOI: 10.1080/14397595.2018.1542962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
152 Ong SY, Gurrin LC, Dolling L, Dixon J, Nicoll AJ, Wolthuizen M, Wood EM, Anderson GJ, Ramm GA, Allen KJ, Olynyk JK, Crawford D, Ramm LE, Gow P, Durrant S, Powell LW, Delatycki MB. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. Lancet Haematol 2017;4:e607-14. [PMID: 29195602 DOI: 10.1016/S2352-3026(17)30214-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
153 Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016;29:445-53. [PMID: 27708509 DOI: 10.20524/aog.2016.0046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
154 Halfon P, Bourlière M, Pénaranda G, Cacoub P. [Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection]. Rev Med Interne 2006;27:751-61. [PMID: 16815598 DOI: 10.1016/j.revmed.2006.03.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
155 Zhang J, Du X, Zhou Z, Lv F, Yu Y. Spleen thickness can predict significant liver pathology in patients with chronic hepatitis B with persistently normal alanine aminotransferase or minimally raised alanine aminotransferase: a retrospective study. J Int Med Res 2019;47:122-32. [PMID: 30213226 DOI: 10.1177/0300060518796760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Takahashi H, Ono N, Eguchi Y, Eguchi T, Kitajima Y, Kawaguchi Y, Nakashita S, Ozaki I, Mizuta T, Toda S. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010;30:538-545. [PMID: 19874490 DOI: 10.1111/j.1478-3231.2009.02130.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 155] [Article Influence: 12.4] [Reference Citation Analysis]
157 Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453-1464. [PMID: 30765123 DOI: 10.1016/s0140-6736(18)32111-1] [Cited by in Crossref: 207] [Cited by in F6Publishing: 77] [Article Influence: 69.0] [Reference Citation Analysis]
158 Wang Y, Xu MY, Zheng RD, Xian JC, Xu HT, Shi JP, Li SB, Qu Y, Dong YW, Lu LG. Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. Hepatol Res. 2013;43:441-451. [PMID: 23006433 DOI: 10.1111/j.1872-034x.2012.01094.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
159 Zeremski M, Martinez A. Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders. Clin Pharmacol Drug Dev 2017;6:164-8. [PMID: 28263455 DOI: 10.1002/cpdd.312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
160 Fraquelli M, Cassinerio E, Roghi A, Rigamonti C, Casazza G, Colombo M, Massironi S, Conte D, Cappellini MD. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. Am J Hematol 2010;85:564-8. [DOI: 10.1002/ajh.21752] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
161 Barreto AVMS, Domingues ALC, Diniz GTN, Cavalcanti AMS, Lopes EP, Montenegro SML, Morais CNL. The Coutinho index as a simple tool for screening patients with advanced forms of Schistosomiasis mansoni: a validation study. Trans R Soc Trop Med Hyg 2021:trab040. [PMID: 33728455 DOI: 10.1093/trstmh/trab040] [Reference Citation Analysis]
162 Maor Y, Halfon P, Bashari D, Pénaranda G, Morali G, Klar R, Bar-meir S, Martinowitz U, Oren R. Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C. Haemophilia 2010;16:148-54. [DOI: 10.1111/j.1365-2516.2009.02092.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
163 Aita JS, Harrison SA. Liver biopsy versus noninvasive testing in chronic hepatitis C: Where do we stand in 2008? Curr hepatitis rep 2008;7:51-9. [DOI: 10.1007/s11901-008-0008-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
164 Calès P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, Bourlière M, de Muret A, Sturm N. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008;28:1352-1362. [PMID: 18492022 DOI: 10.1111/j.1478-3231.2008.01789.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 5.8] [Reference Citation Analysis]
165 Guibal A, Renosi G, Rode A, Scoazec JY, Guillaud O, Chardon L, Munteanu M, Dumortier J, Collin F, Lefort T. Shear wave elastography: An accurate technique to stage liver fibrosis in chronic liver diseases. Diagn Interv Imaging. 2016;97:91-99. [PMID: 26655870 DOI: 10.1016/j.diii.2015.11.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.9] [Reference Citation Analysis]
166 Crawford DHG, Murphy TL, Ramm LE, Fletcher LM, Clouston AD, Anderson GJ, Subramaniam VN, Powell LW, Ramm GA. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009;49:418-25. [DOI: 10.1002/hep.22650] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
167 Guha I, Rosenberg W. Noninvasive Assessment of Liver Fibrosis: Serum Markers, Imaging, and Other Modalities. Clinics in Liver Disease 2008;12:883-900. [DOI: 10.1016/j.cld.2008.07.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
168 Leroy V, Sturm N, Faure P, Trocme C, Marlu A, Hilleret MN, Morel F, Zarski JP. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61:28-34. [PMID: 24631902 DOI: 10.1016/j.jhep.2014.02.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
169 Ho AS, Cheng CC, Lee SC, Liu ML, Lee JY, Wang WM, Wang CC. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010;17:58. [PMID: 20630109 DOI: 10.1186/1423-0127-17-58] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
170 Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, Nakchbandi IA. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol. 2010;45:349-356. [PMID: 20017652 DOI: 10.3109/00365520903490606] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
171 Maor Y, Calès P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Pénaranda G, Bar-meir S, Martinowitz U, Halfon P. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007;13:722-9. [DOI: 10.1111/j.1365-2516.2007.01548.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
172 Ong SY, Dolling L, Dixon JL, Nicoll AJ, Gurrin LC, Wolthuizen M, Wood EM, Anderson GJ, Ramm GA, Allen KJ, Olynyk JK, Crawford D, Kava J, Ramm LE, Gow P, Durrant S, Powell LW, Delatycki MB. Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron). BMJ Open 2015;5:e008938. [PMID: 26270952 DOI: 10.1136/bmjopen-2015-008938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
173 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease 2019;51:183-9. [DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
174 Cano A, Mariño Z, Millet O, Martínez-Arranz I, Navasa M, Falcón-Pérez JM, Pérez-Cormenzana M, Caballería J, Embade N, Forns X, Bosch J, Castro A, Mato JM. A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. Sci Rep 2017;7:10497. [PMID: 28874799 DOI: 10.1038/s41598-017-10807-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
175 Meng F, Zheng Y, Zhang Q, Mu X, Xu X, Zhang H, Ding L. Noninvasive evaluation of liver fibrosis using real-time tissue elastography and transient elastography (FibroScan). J Ultrasound Med. 2015;34:403-410. [PMID: 25715361 DOI: 10.7863/ultra.34.3.403] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
176 Park SH, Kim DJ, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Noninvasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: Do new biomarkers improve the accuracy? Clinical Biochemistry 2010;43:877-81. [DOI: 10.1016/j.clinbiochem.2010.04.063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
177 Attallah AM, El-far M, Malak CAA, Omran MM, Farid K, Hussien MA, Albannan MS, Attallah AA, Elbendary MS, Elbesh DA, Elmenier NA, Abdallah MO. Fibro-check: a combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients. Annals of Hepatology 2015;14:225-33. [DOI: 10.1016/s1665-2681(19)30785-9] [Cited by in Crossref: 12] [Article Influence: 1.7] [Reference Citation Analysis]
178 Cequera A, García de León Méndez MC. [Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Rev Gastroenterol Mex 2014;79:187-99. [PMID: 24954541 DOI: 10.1016/j.rgmx.2014.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
179 Elsebae MM, Abu-Zekri NB. A study of the effect of splenectomy on hepatic functional reserve and structural damage in patients with chronic hepatitis C virus infection by non-invasive serum markers. A prospective study. Int J Surg 2008;6:362-6. [PMID: 18662898 DOI: 10.1016/j.ijsu.2008.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
180 Kang W, Kim SU, Ahn SH. Non-invasive prediction of forthcoming cirrhosis-related complications. World J Gastroenterol 2014; 20(10): 2613-2623 [PMID: 24627597 DOI: 10.3748/wjg.v20.i10.2613] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
181 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
182 Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, Bulsara M, Speers DJ, Macquillan G, Ching HLI, Kontorinis N, Cheng W, Flexman J, Fermoyle S, Rigby P, Walsh L, Mcleod D, Adams LA. Comparison of noninvasive models of fibrosis in chronic hepatitis B. Hepatol Int 2012;6:457-67. [DOI: 10.1007/s12072-011-9296-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
183 Koizumi Y, Hirooka M, Kisaka Y, Konishi I, Abe M, Murakami H, Matsuura B, Hiasa Y, Onji M. Liver fibrosis in patients with chronic hepatitis C: noninvasive diagnosis by means of real-time tissue elastography--establishment of the method for measurement. Radiology 2011;258:610-7. [PMID: 21273523 DOI: 10.1148/radiol.10100319] [Cited by in Crossref: 103] [Cited by in F6Publishing: 83] [Article Influence: 9.4] [Reference Citation Analysis]
184 Karagöz E, Tanoğlu A, Ülçay A, Erdem H, Turhan V, Kara M, Yazgan Y. Mean platelet volume and red cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2016;28:744-8. [PMID: 27101403 DOI: 10.1097/MEG.0000000000000647] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
185 Martyn-simmons C, Rosenberg W, Cross R, Wong T, Smith C, Barker J. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. Br J Dermatol 2014;171:267-73. [DOI: 10.1111/bjd.12782] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
186 Attallah AM, Omran D, Omran MM, Albannan MS, Zayed RA, Saif S, Farid A, Hassany M, Yosry A. Fibro-Mark: a panel of laboratory parameters for predicting significant fibrosis in chronic hepatitis C patients. Br J Biomed Sci 2018;75:19-23. [PMID: 28945150 DOI: 10.1080/09674845.2017.1362950] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
187 Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015; 21(41): 11567-11583 [PMID: 26556987 DOI: 10.3748/wjg.v21.i41.11567] [Cited by in CrossRef: 120] [Cited by in F6Publishing: 105] [Article Influence: 17.1] [Reference Citation Analysis]
188 Bailly F, Ahmed SN, Pradat P, Trepo C. Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther 2010;8:379-95. [PMID: 20377334 DOI: 10.1586/eri.10.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
189 Arain SA, Jamal Q, Omair A. "Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C. World J Gastroenterol 2011; 17(41): 4607-4613 [PMID: 22147967 DOI: 10.3748/wjg.v17.i41.4607] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
190 Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol. 2012;4:11-17. [PMID: 22312451 DOI: 10.5754/hge12064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
191 Benlloch S, Heredia L, Barquero C, Rayón J, Pina R, Aguilera V, Prieto M, Berenguer M. Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients: Liver Transplantation HCV Fibrosis Index. Liver Transpl 2009;15:1798-807. [DOI: 10.1002/lt.21919] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
192 Bonder A, Tapper EB, Afdhal NH. Contemporary Assessment of Hepatic Fibrosis. Clinics in Liver Disease 2015;19:123-34. [DOI: 10.1016/j.cld.2014.09.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
193 Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, Koziel MJ, Graham C, Tumilty S, Skolnik P, Stuver S, Horsburgh RC, Cotton D. Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection. American Journal of Gastroenterology 2010;105:1346-53. [DOI: 10.1038/ajg.2009.746] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 9.3] [Reference Citation Analysis]
194 Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. European Journal of Gastroenterology & Hepatology 2017;29:289-96. [DOI: 10.1097/meg.0000000000000789] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
195 Forbes TP, Najarro M. Ion mobility spectrometry nuisance alarm threshold analysis for illicit narcotics based on environmental background and a ROC-curve approach. Analyst 2016;141:4438-46. [PMID: 27206280 DOI: 10.1039/c6an00844e] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
196 Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abdelmalek MF. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018;2:1344-1355. [PMID: 30411081 DOI: 10.1002/hep4.1237] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
197 Zhang GM, Xia YJ. Reference Intervals of Fibrosis Index Based on Four Indicators in Healthy Elderly Chinese. J Clin Lab Anal 2016;30:645-8. [PMID: 26953257 DOI: 10.1002/jcla.21916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Dighe M, Bruce M. Elastography of Diffuse Liver Diseases. Semin Roentgenol 2016;51:358-66. [PMID: 27743570 DOI: 10.1053/j.ro.2016.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
199 Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, Barnes E, Klenerman P, Dwek RA, Zitzmann N. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One 2012;7:e39603. [PMID: 22761838 DOI: 10.1371/journal.pone.0039603] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
200 Pankow JS, Boerwinkle E, Adams PC, Guallar E, Leiendecker-Foster C, Rogowski J, Eckfeldt JH. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res 2008;152:3-10. [PMID: 18593631 DOI: 10.1016/j.trsl.2008.05.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
201 Gheorghe G, Bungău S, Ceobanu G, Ilie M, Bacalbaşa N, Bratu OG, Vesa CM, Găman MA, Diaconu CC. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc 2021;120:794-803. [PMID: 32861550 DOI: 10.1016/j.jfma.2020.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
202 Behairy BES, Sira MM, Zalata KR, Salama ESE, Abd-Allah MA. Transient elastography compared to liver biopsy and morphometry for predicting fibrosis in pediatric chronic liver disease: Does etiology matter? World J Gastroenterol 2016; 22(16): 4238-4249 [PMID: 27122674 DOI: 10.3748/wjg.v22.i16.4238] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
203 Morikawa H, Kawada N. Non-invasive diagnosis of liver fibrosis. Clin J Gastroenterol 2011;4:283-91. [DOI: 10.1007/s12328-011-0248-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
204 Toson el-SA, Shiha GE, El-Mezayen HA, El-Sharkawy AM. Diagnostic performance of T lymphocyte subpopulations in assessment of liver fibrosis stages in hepatitis C virus patients: simple noninvasive score. Eur J Gastroenterol Hepatol 2016;28:931-9. [PMID: 27159125 DOI: 10.1097/MEG.0000000000000656] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
205 Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Combining non-invasive methods for assessment of liver fibrosis. Gastroentérologie Clinique et Biologique 2008;32:73-9. [DOI: 10.1016/s0399-8320(08)73996-4] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
206 Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 2012;19 Suppl 1:18-32. [PMID: 22233410 DOI: 10.1111/j.1365-2893.2011.01518.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
207 Yoshioka K, Kawabe N, Hashimoto S. Transient elastography: Applications and limitations. Hepatology Research 2008;38:1063-8. [DOI: 10.1111/j.1872-034x.2008.00386.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
208 Louten J, Beach M, Palermino K, Weeks M, Holenstein G. MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomark Insights. 2015;10:25-52. [PMID: 26819546 DOI: 10.4137/bmi.s29512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
209 Barreto AV, Alecrim VM, Medeiros TB, Domingues AL, Lopes EP, Martins JR, Nader HB, Diniz GT, Montenegro SM, Morais CN. New index for the diagnosis of liver fibrosis in Schistosomiasis mansoni. Arq Gastroenterol 2017;54:51-6. [PMID: 28079240 DOI: 10.1590/S0004-2803.2017v54n1-10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
210 Guéchot J. [Noninvasive assessment of liver fibrosis in patients with chronic hepatitis virus C]. Presse Med. 2006;35:1317-1326. [PMID: 16969327 DOI: 10.1016/s0755-4982(06)74811-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
211 Deuffic-burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P. Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis? Journal of Hepatology 2017;66:304-12. [DOI: 10.1016/j.jhep.2016.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
212 Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'Alteroche L, Portal I, Lapidus N, Pol S, Carrat F; ANRS/AFEF Hepather study group. Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clin Res Hepatol Gastroenterol 2021;45:101713. [PMID: 33930591 DOI: 10.1016/j.clinre.2021.101713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
213 Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2011;106:1255-1263. [PMID: 21468012 DOI: 10.1038/ajg.2011.100] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
214 Mbaye PS, Sarr A, Sire JM, Evra ML, Ba A, Daveiga J, Diallo A, Fall F, Chartier L, Simon F, Vray M. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load. PLoS One 2011;6:e22291. [PMID: 21799814 DOI: 10.1371/journal.pone.0022291] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
215 Corti A, Fierabracci V, Caponi L, Paolicchi A, Lorenzini E, Campani D, Belcastro E, Franzini M. Effect of the three-dimensional organization of liver cells on the biogenesis of the γ-glutamyltransferase fraction pattern. Biomarkers. 2016;21:441-448. [PMID: 27027926 DOI: 10.3109/1354750x.2016.1153719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
216 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 368] [Article Influence: 41.1] [Reference Citation Analysis]
217 Elawdi HA, Franzini M, Paolicchi A, Emdin M, Fornaciari I, Fierabracci V, De Simone P, Carrai P, Filipponi F. Circulating gamma-glutamyltransferase fractions in cirrhosis. Liver Int. 2014;34:e191-e199. [PMID: 24387676 DOI: 10.1111/liv.12455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
218 Guéchot J. Non-invasive evaluation of liver fibrosis: More well-validated tests available for patient management. Liver Int 2015;35:1643-5. [DOI: 10.1111/liv.12790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
219 Chládek J, S̆imková M, Vanec̆ková J, Hroch M, Vávrová J, Hůlek P. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers: Markers of live fibrosis in psoriasis. Journal of the European Academy of Dermatology and Venereology 2013;27:1007-14. [DOI: 10.1111/j.1468-3083.2012.04643.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
220 de Lédinghen V, Poynard T, Wartelle C, Rosenthal E. [Non-invasive evaluation of liver fibrosis in hepatitis C]. Gastroenterol Clin Biol 2008;32:S90-5. [PMID: 18675186 DOI: 10.1016/S0399-8320(08)73271-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
221 Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, Fung J, Wong DK, Yuen MF. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 2011;6:e23077. [PMID: 21853071 DOI: 10.1371/journal.pone.0023077] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
222 Cequera A, García de León Méndez M. Biomarkers for liver fibrosis: Advances, advantages and disadvantages. Revista de Gastroenterología de México (English Edition) 2014;79:187-99. [DOI: 10.1016/j.rgmxen.2014.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
223 Powell LW. Overview: Liver disease and transplantation. Journal of Gastroenterology and Hepatology 2009;24:S97-S104. [DOI: 10.1111/j.1440-1746.2009.06079.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
224 Neuman MG, Cohen LB, Nanau RM. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem. 2016;49:302-315. [PMID: 26188920 DOI: 10.1016/j.clinbiochem.2015.07.019] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
225 Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019;48:281-289. [PMID: 31046975 DOI: 10.1016/j.gtc.2019.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
226 Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: A short survey. World J Gastroenterol 2009; 15(20): 2433-2440 [PMID: 19468990 DOI: 10.3748/wjg.15.2433] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
227 Więcek S, Woś H, Pogorzelski A, Kordys-Darmolinska B, Mazurek H, Grzybowska-Chlebowczyk U. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis. Mediators Inflamm 2020;2020:5696185. [PMID: 32308556 DOI: 10.1155/2020/5696185] [Reference Citation Analysis]
228 Chang XJ, Sun C, Chen Y, Li XD, Yu ZJ, Dong Z, Bai WL, Wang XD, Li ZQ, Chen D, Du WJ, Liao H, Jiang QY, Sun LJ, Li YY, Zhang CH, Xu DP, Chen YP, Li Q, Yang YP. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol 2019; 25(32): 4764-4778 [PMID: 31528100 DOI: 10.3748/wjg.v25.i32.4764] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
229 Drescher HK, Weiskirchen S, Weiskirchen R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells 2019;8:E845. [PMID: 31394730 DOI: 10.3390/cells8080845] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
230 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Ayonrinde OT, Olynyk JK. PAHA model: an alternative non-invasive predictor of liver cirrhosis in patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2010;25:3-4. [PMID: 20136968 DOI: 10.1111/j.1440-1746.2009.06041.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
232 Carrión JA, Navasa M, Buti M, Torras X, Xiol X, Vergara M, Planas R, Solà R, Forns X. Elastografía hepática. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2011;34:504-10. [DOI: 10.1016/j.gastrohep.2011.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
233 Fraga CG, Melville AM, Wright BW. ROC-curve approach for determining the detection limit of a field chemical sensor. Analyst 2007;132:230-6. [DOI: 10.1039/b607843e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
234 Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017;51:268-77. [PMID: 27380461 DOI: 10.1097/MCG.0000000000000581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
235 Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians AIDS Care (Chic). 2012;11:311-320. [PMID: 22828983 DOI: 10.1177/1545109712453939] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
236 Calès P, Boursier J, Ducancelle A, Oberti F, Hubert I, Hunault G, de Lédinghen V, Zarski JP, Salmon D, Lunel F. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver Int. 2014;34:907-917. [PMID: 24102852 DOI: 10.1111/liv.12327] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
237 Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le Tallec V, Oberti F, Fouchard-Hubert I, Dib N. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 2009;29:1507-1515. [PMID: 19725892 DOI: 10.1111/j.1478-3231.2009.02101.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
238 Cheung KJ, Libbrecht L, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol. 2010;22:1066-1073. [PMID: 20186066 DOI: 10.1097/MEG.0b013e328337d602] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
239 Gonzalez HC, Jafri SM, Gordon SC. Role of Liver Biopsy in the Era of Direct-Acting Antivirals. Curr Gastroenterol Rep 2013;15. [DOI: 10.1007/s11894-012-0307-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
240 Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-921. [PMID: 17705266 DOI: 10.1002/hep.21835] [Cited by in Crossref: 251] [Cited by in F6Publishing: 239] [Article Influence: 16.7] [Reference Citation Analysis]
241 Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy. Am J Gastroenterology 2007;102:2589-600. [DOI: 10.1111/j.1572-0241.2007.01466.x] [Cited by in Crossref: 233] [Cited by in F6Publishing: 219] [Article Influence: 15.5] [Reference Citation Analysis]
242 Shire NJ, Rao MB, Succop P, Buncher CR, Andersen JA, Butt AA, Chung RT, Sherman KE. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol. 2009;7:471-480, 480.e1-2. [PMID: 19268724 DOI: 10.1016/j.cgh.2008.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
243 Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am. 2011;40:507-521. [PMID: 21893271 DOI: 10.1016/j.gtc.2011.06.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
244 Huang Y, Adams LA, MacQuillan G, Speers D, Joseph J, Bulsara MK, Jeffrey GP. Serum models accurately predict liver-related clinical outcomes in chronic hepatitis C. J Gastroenterol Hepatol. 2016;31:1736-1741. [PMID: 26945918 DOI: 10.1111/jgh.13333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
245 Guéchot J, Edrief S, Lasnier E, Küper R. Automated assay of hyaluronic acid in serum. Immuno-analyse & Biologie Spécialisée 2008;23:148-52. [DOI: 10.1016/j.immbio.2008.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
246 Bosselut N, Taibi L, Guéchot J, Zarski JP, Sturm N, Gelineau MC, Poggi B, Thoret S, Lasnier E, Baudin B. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy. Clin Chim Acta. 2013;415:63-68. [PMID: 23022619 DOI: 10.1016/j.cca.2012.09.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
247 Fuster D, García-Calvo X, Zuluaga P, Bolao F, Muga R. Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. World J Gastroenterol 2021; 27(23): 3223-3237 [PMID: 34163107 DOI: 10.3748/wjg.v27.i23.3223] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Davies J, Smith EL, Littlejohn M, Edwards R, Sozzi V, Jackson K, Mcguire K, Binks P, Cowie BC, Locarnini S, Davis JS, Tong SYC. Towards Genotype-Specific Care for Chronic Hepatitis B: The First 6 Years Follow Up From the CHARM Cohort Study. Open Forum Infect Dis 2019;6:ofz469. [PMID: 32864387 DOI: 10.1093/ofid/ofz469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
249 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
250 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007;11:1031-1051. [PMID: 17979881 DOI: 10.1111/j.1582-4934.2007.00092.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
251 Török NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol. 2008;43:315-321. [PMID: 18592147 DOI: 10.1007/s00535-008-2181-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
252 Nazareth S, Kontorinis N, Muwanwella N, Hamilton A, Leembruggen N, Cheng WS. Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth. J Telemed Telecare 2013;19:101-6. [DOI: 10.1258/jtt.2012.120612] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
253 Zhou K, Gao CF, Zhao YP, Liu HL, Zheng RD, Xian JC, Xu HT, Mao YM, Zeng MD, Lu LG. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25:1569-1577. [PMID: 20796157 DOI: 10.1111/j.1440-1746.2010.06383.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 5.9] [Reference Citation Analysis]
254 Ozkurt H, Keskiner F, Karatag O, Alkim C, Erturk SM, Basak M. Diffusion Weighted MRI for Hepatic Fibrosis: Impact of b-Value. Iran J Radiol 2014;11:e3555. [PMID: 24693297 DOI: 10.5812/iranjradiol.3555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
255 Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, Vernazza P, Opravil M, Weber R. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PLoS One. 2015;10:e0138838. [PMID: 26418061 DOI: 10.1371/journal.pone.0138838] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
256 Abdelgawad ME, El-Zakzok H, Salah M, El-Mezayen HA. Diagnostic accuracy of hepatocyte growth factor, Fas/CD95 and Endostatin for non-invasive assessment of hepatic fibrosis in biopsy-proven hepatitis C virus patients. Infect Genet Evol 2020;85:104526. [PMID: 32890764 DOI: 10.1016/j.meegid.2020.104526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Mendes LC, Stucchi RS, Vigani AG. Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies. Hepat Med. 2018;10:13-22. [PMID: 29662329 DOI: 10.2147/hmer.s125234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
258 Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-fridlund D, Tran A, Rosenthal E, Wartelle-bladou C, Delasalle P, Oules V, Portal I, Castellani P, Lecomte L, Rosenthal-allieri MA, Halfon P. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Alimentary Pharmacology & Therapeutics 2008;28:458-67. [DOI: 10.1111/j.1365-2036.2008.03742.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
259 Boursier J, de Ledinghen V, Leroy V, Anty R, Francque S, Salmon D, Lannes A, Bertrais S, Oberti F, Fouchard-hubert I, Calès P. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. Journal of Hepatology 2017;66:1158-65. [DOI: 10.1016/j.jhep.2017.01.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
260 Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007; 13(32): 4287-4294 [PMID: 17708599 DOI: 10.3748/wjg.v13.i32.4287] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
261 Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 2011;25:291-303. [PMID: 21497746 DOI: 10.1016/j.bpg.2011.02.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 8.3] [Reference Citation Analysis]
262 Bottero J, Lacombe K, Guéchot J, Serfaty L, Miailhes P, Bonnard P, Wendum D, Molina JM, Lascoux-Combe C, Girard PM. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J Hepatol. 2009;50:1074-1083. [PMID: 19398234 DOI: 10.1016/j.jhep.2009.01.022] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
263 Beckebaum S, Iacob S, Klein CG, Dechêne A, Varghese J, Baba HA, Sotiropoulos GC, Paul A, Gerken G, Cicinnati VR. Assessment of Allograft Fibrosis by Transient Elastography and Noninvasive Biomarker Scoring Systems in Liver Transplant Patients. Transplantation 2010;89:983-93. [DOI: 10.1097/tp.0b013e3181cc66ca] [Cited by in Crossref: 53] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
264 Jaroszewicz J, Flisiak-jackiewicz M, Lebensztejn D, Flisiak R. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opinion on Investigational Drugs 2015;24:1229-39. [DOI: 10.1517/13543784.2015.1057568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
265 Boursier J, Guillaume M, Leroy V, Irlès M, Roux M, Lannes A, Foucher J, Zuberbuhler F, Delabaudière C, Barthelon J, Michalak S, Hiriart JB, Peron JM, Gerster T, Le Bail B, Riou J, Hunault G, Merrouche W, Oberti F, Pelade L, Fouchard I, Bureau C, Calès P, de Ledinghen V. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019;71:389-396. [PMID: 31102719 DOI: 10.1016/j.jhep.2019.04.020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
266 Wu YM, Xu N, Hu JY, Xu XF, Wu WX, Gao SX, Zhu WJ, Wu WL, Shen XZ, Wang JY, Wu SD. A simple noninvasive index to predict significant liver fibrosis in patients with advanced schistosomiasis japonica. Parasitol Int 2013;62:283-8. [PMID: 23466574 DOI: 10.1016/j.parint.2013.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
267 Iacob S, Cicinnati V, Kabar I, Hüsing-Kabar A, Radtke A, Iacob R, Baba H, Schmidt HH, Paul A, Beckebaum S. Prediction of late allograft dysfunction following liver transplantation by immunological blood biomarkers. Transpl Immunol 2021;69:101448. [PMID: 34391882 DOI: 10.1016/j.trim.2021.101448] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
268 Calès P, Zarski JP, Marc Chapplain J, Bertrais S, Sturm N, Michelet C, Babany G, Chaigneau J, Eddine Charaf M; multicentric groups (Fibrosys, ANRS HC 12, Fibrostop). Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry: Precise evaluation of fibrosis progression. Journal of Viral Hepatitis 2012;19:e143-53. [DOI: 10.1111/j.1365-2893.2011.01531.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
269 Day JW, Rosenberg WM. The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. Br J Hosp Med 2018;79:694-9. [DOI: 10.12968/hmed.2018.79.12.694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
270 Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47:789-798. [PMID: 18175357 DOI: 10.1002/hep.22099] [Cited by in Crossref: 127] [Cited by in F6Publishing: 116] [Article Influence: 9.1] [Reference Citation Analysis]
271 Gressner AM, Rizk M, Gao C, Gressner OA. Potential novel biomarkers for monitoring the fibrogenic process in liver. Arab Journal of Gastroenterology 2010;10:S12-6. [DOI: 10.1016/j.ajg.2009.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
272 Kim SU, Han KH, Ahn SH. Non-invasive assessment of liver fibrosis: time to move from cross-sectional studies to longitudinal ones. J Gastroenterol Hepatol. 2010;25:1472-1473. [PMID: 20796140 DOI: 10.1111/j.1440-1746.2010.06432.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
273 Das SK, Vasudevan DM. Genesis of hepatic fibrosis and its biochemical markers. Scand J Clin Lab Invest. 2008;68:260-269. [PMID: 18609066 DOI: 10.1080/00365510701668516] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
274 Lewin M, Poujol-Robert A, Boëlle PY, Wendum D, Lasnier E, Viallon M, Guéchot J, Hoeffel C, Arrivé L, Tubiana JM. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology. 2007;46:658-665. [PMID: 17663420 DOI: 10.1002/hep.21747] [Cited by in Crossref: 199] [Cited by in F6Publishing: 181] [Article Influence: 13.3] [Reference Citation Analysis]
275 Calès P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008;32:40-51. [PMID: 18973845 DOI: 10.1016/s0399-8320(08)73992-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
276 Brady CW, Mchutchison JG, Patel K. Fibrosis markers in hepatitis C. Curr hepatitis rep 2006;5:86-93. [DOI: 10.1007/s11901-006-0010-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
277 Attallah AM, Abdallah SO, Attallah AA, Omran MM, Farid K, Nasif WA, Shiha GE, Abdel-aziz AF, Rasafy N, Shaker YM. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients. Annals of Hepatology 2013;12:44-53. [DOI: 10.1016/s1665-2681(19)31384-5] [Cited by in Crossref: 21] [Article Influence: 2.3] [Reference Citation Analysis]
278 Halfon P, Bourlière M, Pénaranda G, Cacoub P. Intérêt et limites des méthodes non invasives de prédiction de la fibrose hépatique au cours de l'hépatite C: une alternative à la biopsie hépatique. La Presse Médicale 2007;36:457-66. [DOI: 10.1016/j.lpm.2007.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
279 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
280 Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, Morel F, Zarski JP. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775-782. [PMID: 17321634 DOI: 10.1016/j.jhep.2006.12.013] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 10.9] [Reference Citation Analysis]
281 Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15(18): 2190-2203 [PMID: 19437558 DOI: 10.3748/wjg.15.2190] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
282 Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard-Hubert I, Oberti F, Rousselet MC, Calès P. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40:178-188. [PMID: 24889599 DOI: 10.1111/apt.12813] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
283 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
284 Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB, Park YN. Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci. 2011;56:555-563. [PMID: 20585981 DOI: 10.1007/s10620-010-1305-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
285 Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res. 2008;32:1031-1039. [PMID: 18422837 DOI: 10.1111/j.1530-0277.2008.00664.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
286 Portilla J, López-Burgos A, Saiz-De-La-Hoya-Zamácola P, Sánchez-Payá J, Bedía-Collantes M, Faraco-Atienzar I, Lissen E. [Utility of 2 biochemical models predictive of liver fibrosis grade in prison inmates with hepatitis C]. Gastroenterol Hepatol 2009;32:387-94. [PMID: 19477553 DOI: 10.1016/j.gastrohep.2009.01.176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
287 Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, Reitz R, Nasser I, Afdhal NH. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7:696-701. [PMID: 19514117 DOI: 10.1016/j.cgh.2009.01.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
288 Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med. 2006;260:142-150. [PMID: 16882278 DOI: 10.1111/j.1365-2796.2006.01673.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
289 Rath T, Roderfeld M, Güler C, Wenzel C, Graf J, Beitinger F, Roeb E, Zachoval R. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scandinavian Journal of Gastroenterology 2011;46:1369-80. [DOI: 10.3109/00365521.2011.613949] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
290 Ianni Filho D, Boin IFSF, Yamanaka A. BIOIMPEDANCE: NEW APPROACH TO NON-INVASIVE DETECTION OF LIVER FIBROSIS - A PILOT STUDY. Arq Gastroenterol 2018;55:2-6. [PMID: 29561971 DOI: 10.1590/S0004-2803.201800000-02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
291 Gressner OA, Gao C. Monitoring fibrogenic progression in the liver. Clin Chim Acta. 2014;433:111-122. [PMID: 24607331 DOI: 10.1016/j.cca.2014.02.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
292 Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015; 21(39): 11077-11087 [PMID: 26494963 DOI: 10.3748/wjg.v21.i39.11077] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
293 Huang Y, de Boer WB, Adams LA, MacQuillan G, Rossi E, Rigby P, Raftopoulos SC, Bulsara M, Jeffrey GP. Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int 2013;33:1249-56. [PMID: 23617278 DOI: 10.1111/liv.12184] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
294 Chinnaratha MA, Jeffrey GP, Macquillan G, Rossi E, de Boer BW, Speers DJ, Adams LA. Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models. Liver Int 2014;34:720-7. [DOI: 10.1111/liv.12306] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
295 Bracht T, Schweinsberg V, Trippler M, Kohl M, Ahrens M, Padden J, Naboulsi W, Barkovits K, Megger DA, Eisenacher M, Borchers CH, Schlaak JF, Hoffmann A, Weber F, Baba HA, Meyer HE, Sitek B. Analysis of Disease-Associated Protein Expression Using Quantitative Proteomics—Fibulin-5 Is Expressed in Association with Hepatic Fibrosis. J Proteome Res 2015;14:2278-86. [DOI: 10.1021/acs.jproteome.5b00053] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
296 Babaei Z, Parsian H. Hyaluronic acid algorithm-based models for assessment of liver fibrosis: translation from basic science to clinical application. Hepatobiliary Pancreat Dis Int 2016;15:131-40. [PMID: 27020628 DOI: 10.1016/s1499-3872(16)60062-0] [Reference Citation Analysis]
297 Hamesch K, Mandorfer M, Pereira VM, Moeller LS, Pons M, Dolman GE, Reichert MC, Schneider CV, Woditsch V, Voss J, Lindhauer C, Fromme M, Spivak I, Guldiken N, Zhou B, Arslanow A, Schaefer B, Zoller H, Aigner E, Reiberger T, Wetzel M, Siegmund B, Simões C, Gaspar R, Maia L, Costa D, Bento-miranda M, van Helden J, Yagmur E, Bzdok D, Stolk J, Gleiber W, Knipel V, Windisch W, Mahadeva R, Bals R, Koczulla R, Barrecheguren M, Miravitlles M, Janciauskiene S, Stickel F, Lammert F, Liberal R, Genesca J, Griffiths WJ, Trauner M, Krag A, Trautwein C, Strnad P. Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. Gastroenterology 2019;157:705-719.e18. [DOI: 10.1053/j.gastro.2019.05.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
298 Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20(11): 2854-2866 [PMID: 24659877 DOI: 10.3748/wjg.v20.i11.2854] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
299 Foucher J, Reiller B, Jullien V, Léal F, di Cesare ES, Merrouche W, Delile JM, de Lédinghen V. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. J Viral Hepat 2009;16:121-31. [PMID: 19175876 DOI: 10.1111/j.1365-2893.2008.01050.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
300 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
301 Nguyen-khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, Mueller S, de Ledinghen V, Stärkel P, Gyune Kim S, Fernandez M, Madsen B, Naveau S, Krag A, Perlemuter G, Ziol M, Chatelain D, Diouf M. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. The Lancet Gastroenterology & Hepatology 2018;3:614-25. [DOI: 10.1016/s2468-1253(18)30124-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
302 Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepat Mon 2012;12:77-84. [PMID: 22509183 DOI: 10.5812/hepatmon.829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
303 Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: A comparative study. World J Gastroenterol 2010; 16(4): 501-507 [PMID: 20101779 DOI: 10.3748/wjg.v16.i4.501] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
304 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016; 22(4): 1367-1381 [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
305 Calès P, Halfon P, Batisse D, Carrat F, Perré P, Penaranda G, Guyader D, d’Alteroche L, Fouchard-Hubert I, Michelet C. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol. 2010;53:238-244. [PMID: 20493576 DOI: 10.1016/j.jhep.2010.03.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
306 Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20(32): 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 97] [Article Influence: 14.6] [Reference Citation Analysis]
307 Sagnelli C, Martini S, Pisaturo M, Pasquale G, Macera M, Zampino R, Coppola N, Sagnelli E. Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World J Hepatol 2015; 7(24): 2510-2521 [PMID: 26523204 DOI: 10.4254/wjh.v7.i24.2510] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
308 Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P;  FIBROSTIC study group. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013-1021. [PMID: 20850886 DOI: 10.1016/j.jhep.2010.05.035] [Cited by in Crossref: 294] [Cited by in F6Publishing: 271] [Article Influence: 24.5] [Reference Citation Analysis]
309 Attallah AM, Abdallah SO, El Sayed AS, Omran MM, El-Bendary M, Farid K, Kadry M. Non-invasive predictive score of fibrosis stages in chronic hepatitis C patients based on epithelial membrane antigen in the blood in combination with routine laboratory markers. Hepatol Res. 2011;41:1075-1084. [PMID: 22035384 DOI: 10.1111/j.1872-034x.2011.00862.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
310 Lizaola B, Bonder A, Tapper EB, Afdhal N. Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus. Curr Hepatology Rep 2016;15:220-9. [DOI: 10.1007/s11901-016-0311-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
311 Saludes V, González V, Planas R, Matas L, Ausina V, Martró E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol 2014; 20(13): 3431-3442 [PMID: 24707126 DOI: 10.3748/wjg.v20.i13.3431] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
312 El-attar MM, Rashed HG, Sewify EM, Hassan HE. A suggested algorithm for using serum biomarkers for the diagnosis of liver fibrosis in chronic hepatitis C infection. Arab Journal of Gastroenterology 2010;11:206-11. [DOI: 10.1016/j.ajg.2010.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
313 Castera L. Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:541-552. [PMID: 19072402 DOI: 10.1586/17474124.2.4.541] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
314 Enomoto H, Aizawa N, Nakamura H, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Aoki T, Yuri Y, Yoh K. An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. Gastroenterol Res Pract. 2014;2014:351396. [PMID: 24693282 DOI: 10.1155/2014/351396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
315 Ceylan B, Fincanci M, Yardimci C, Eren G, Tözalgan Ü, Müderrisoğlu C, Paşaoğlu E. Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B? Eur J Gastroenterol Hepatol 2013;25:606-12. [PMID: 23325286 DOI: 10.1097/MEG.0b013e32835d08da] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
316 Krawczyk M, Zimmermann S, Hess G, Holz R, Dauer M, Raedle J, Lammert F, Grünhage F. Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease. PLoS One 2017;12:e0173506. [PMID: 28301573 DOI: 10.1371/journal.pone.0173506] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
317 Albhaisi S, Sanyal AJ. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceut Med 2019;33:451-63. [PMID: 31933238 DOI: 10.1007/s40290-019-00305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
318 Moscoso CG, Steer CJ. "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics. Hepat Med 2019;11:109-29. [PMID: 31565001 DOI: 10.2147/HMER.S213397] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
319 Zeng DW, Liu YR, Zhang JM, Zhu YY, Lin S, You J, Li YB, Chen J, Zheng Q, Jiang JJ, Dong J. Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One. 2013;8:e77942. [PMID: 24282481 DOI: 10.1371/journal.pone.0077942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
320 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 23.5] [Reference Citation Analysis]
321 Lin B, Ma Y, Wu S, Liu Y, Liu L, Wu L. Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis. OMICS 2019;23:181-9. [PMID: 30932742 DOI: 10.1089/omi.2019.0035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
322 Pateria P, Jeffrey GP, MacQuillan G, Speers D, Ching H, Chinnaratha MA, Watts GF, Adams LA. The association between chronic hepatitis C infection and cardiovascular risk. Intern Med J 2016;46:63-70. [PMID: 26477784 DOI: 10.1111/imj.12936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
323 Yang LY, Fu J, Peng XF, Pang SY, Gao KK, Chen ZR, He LJ, Wen Z, Wang H, Li L, Wang FH, Yu JK, Xu Y, Gong ST, Xia HM, Liu HY. Validation of aspartate aminotransferase to platelet ratio for diagnosis of liver fibrosis and prediction of postoperative prognosis in infants with biliary atresia. World J Gastroenterol 2015; 21(19): 5893-5900 [PMID: 26019453 DOI: 10.3748/wjg.v21.i19.5893] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
324 Cepeda JA, Solomon SS, Srikrishnan AK, Nandagopal P, Balakrishnan P, Kumar MS, Thomas DL, Sulkowski MS, Mehta SH. Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India. Open Forum Infect Dis 2016;3:ofw156. [PMID: 27704012 DOI: 10.1093/ofid/ofw156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
325 Zeng DW, Dong J, Jiang JJ, Zhu YY, Liu YR. Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase. World J Gastroenterol 2016; 22(43): 9586-9594 [PMID: 27920479 DOI: 10.3748/wjg.v22.i43.9586] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
326 Rosenthal-allieri MA, Tran A, Halfon P, Imbert-bismut F, Munteanu M, Messous D, Peritore M, Poynard T, Bernard A. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 2007;31:815-21. [DOI: 10.1016/s0399-8320(07)73971-4] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
327 Martel-Laferrière V, Wong M, Dieterich DT. HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next? Clin Infect Dis 2014;58:840-7. [PMID: 24178247 DOI: 10.1093/cid/cit714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
328 Casey SP, Kemp WW, McLean CA, Topliss DJ, Adams LA, Roberts SK. A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. Scand J Gastroenterol. 2012;47:836-841. [PMID: 22519948 DOI: 10.3109/00365521.2012.677955] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
329 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
330 Matta B, Lee TH, Patel K. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Curr HIV/AIDS Rep 2016;13:279-88. [PMID: 27485838 DOI: 10.1007/s11904-016-0329-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
331 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
332 Moreno S, García-Samaniego J, Moreno A, Ortega E, Pineda JA, del Romero J, Tural C, von Wichmann MA, Berenguer J, Castro A. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat. 2009;16:249-258. [PMID: 19215579 DOI: 10.1111/j.1365-2893.2009.01088.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
333 Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourlière M, de Muret A, Sturm N, Hunault G, Penaranda G. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem. 2008;41:1368-1376. [PMID: 18655779 DOI: 10.1016/j.clinbiochem.2008.06.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
334 Lejealle C, Castera L. Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B. Curr Hepatology Rep 2018;17:492-501. [DOI: 10.1007/s11901-018-0439-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]